Biomarkers predictive of response to pembrolizumab in head and neck cancer

BACKGROUND: We performed an integrated biomarker evaluation in pembrolizumab‐treated patients with R/M HNSCC enrolled in KEYNOTE‐012 or KEYNOTE‐055. The relationship between biomarkers and HPV status was explored. METHODS: We evaluated PD‐L1 (combined positive score [CPS]), TMB, T‐cell‐inflamed gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfister, David G., Haddad, Robert I., Worden, Francis P., Weiss, Jared, Mehra, Ranee, Chow, Laura Q. M., Liu, Stephen V., Kang, Hyunseok, Saba, Nabil F., Wirth, Lori J., Sukari, Ammar, Massarelli, Erminia, Ayers, Mark, Albright, Andrew, Webber, Andrea L., Mogg, Robin, Lunceford, Jared, Huang, Lingkang, Cristescu, Razvan, Cheng, Jonathan, Seiwert, Tanguy Y., Bauml, Joshua M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067081/
https://www.ncbi.nlm.nih.gov/pubmed/36479637
http://dx.doi.org/10.1002/cam4.5434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067081/
https://www.ncbi.nlm.nih.gov/pubmed/36479637
http://dx.doi.org/10.1002/cam4.5434

Ejemplares similares